AN2 Therapeutics logo

AN2 TherapeuticsNASDAQ: ANTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

25 March 2022

Next earnings report:

28 March 2025

Last dividends:

N/A

Next dividends:

N/A
$38.24 M
-94%vs. 3y high
32%vs. sector
-vs. 3y high
-vs. sector
-91%vs. 3y high
25%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Thu, 21 Nov 2024 00:31:34 GMT
$1.28+$0.23(+21.90%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ANTX Latest News

AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why
zacks.com19 August 2024 Sentiment: NEGATIVE

AN2 Therapeutics (ANTX) falls 66% in a month after terminating its mycobacterium avium complex lung disease study of epetraborole due to unsatisfactory efficacy results.

Why Is AN2 Therapeutics (ANTX) Stock Down 35% Today?
investorplace.com09 August 2024 Sentiment: NEGATIVE

AN2 Therapeutics (NASDAQ: ANTX ) stock is taking a beating on Friday after the company provided an update on its EBO-301 Phase 2/3 study. AN2 Therapeutics notes that information comes from the Phase 2 study of epetraborole as an optimized background regimen (OBR) in treatment-refractory MAC lung disease.

Recent Price Trend in AN2 Therapeutics, Inc. (ANTX) is Your Friend, Here's Why
Zacks Investment Research10 January 2024 Sentiment: POSITIVE

AN2 Therapeutics, Inc. (ANTX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

AN2 Therapeutics, Inc. (ANTX) Is a Great Choice for 'Trend' Investors, Here's Why
Zacks Investment Research06 November 2023 Sentiment: POSITIVE

AN2 Therapeutics, Inc. (ANTX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
Business Wire11 October 2023 Sentiment: POSITIVE

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced two oral presentations and three poster presentations at the Infectious Disease Society of America (IDSA) IDWeek 2023 Conference from October 11-15, 2023 in Boston, Massachusetts. AN2 Therapeutics is currently enrolling patients in the Phase 3 part of its p.

Has AN2 Therapeutics (ANTX) Outpaced Other Medical Stocks This Year?
Zacks Investment Research11 September 2023 Sentiment: POSITIVE

Here is how AN2 Therapeutics, Inc. (ANTX) and Artivion (AORT) have performed compared to their sector so far this year.

AN2 Therapeutics: Boron Chemistry For Infectious Diseases
Seeking Alpha05 May 2023 Sentiment: POSITIVE

AN2 is a developer of rare, infectious disease therapeutics. AN2 leverages its boron chemistry expertise and has a history of a successful sale to Pfizer.

What type of business is AN2 Therapeutics?

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

What sector is AN2 Therapeutics in?

AN2 Therapeutics is in the Healthcare sector

What industry is AN2 Therapeutics in?

AN2 Therapeutics is in the Biotechnology industry

What country is AN2 Therapeutics from?

AN2 Therapeutics is headquartered in United States

When did AN2 Therapeutics go public?

AN2 Therapeutics initial public offering (IPO) was on 25 March 2022

What is AN2 Therapeutics website?

https://www.an2therapeutics.com

Is AN2 Therapeutics in the S&P 500?

No, AN2 Therapeutics is not included in the S&P 500 index

Is AN2 Therapeutics in the NASDAQ 100?

No, AN2 Therapeutics is not included in the NASDAQ 100 index

Is AN2 Therapeutics in the Dow Jones?

No, AN2 Therapeutics is not included in the Dow Jones index

When was AN2 Therapeutics the previous earnings report?

No data

When does AN2 Therapeutics earnings report?

The next expected earnings date for AN2 Therapeutics is 28 March 2025